The search for novel anticancer agents: A differentiation-based assay and analysis of a folklore product

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1027-1033

  Dinnen, Richard D ^a   Ebisuzaki, Kaney ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Anticancer drugs; Differentiation assay; Folk medicine; Oncogene; Vitamin K

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; DACTINOMYCIN; LAPACHOL; LOMUSTINE; PHYTOMENADIONE; PLANT EXTRACT; RETINOIC ACID; VINCRISTINE SULFATE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG STRUCTURE; ERYTHROLEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRADITIONAL MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; MICE; NAPHTHOQUINONES; TUMOR CELLS, CULTURED; VITAMIN K;

EID: 0030945360     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Grever MR, Schepartz SA and Chabner BA: The National Ca Institute: Cancer drug discovery and development program. Semin Oncol 19: 622-638, 1992.
2. Hozumi M: Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. In: Advances in Cancer Research (Klein G and Weinhousc S, eds). New York, Academic Press 1983, Vol 38, pp 121-169.
3. Dinnen RD and Ebisuzaki K: The linking of anticancer drugs, cell cycle blocks, and differentiation: Implications in the search for antineoplastic drugs. Leuk Res 16: 491-495, 1992.
4. Dinnen RD, Robinow CF and Ebisuzaki K: An anticancer drug-sensitive murine erythroleukemia clone: Implications for the mechanism of action of antineoplastic drugs. Cancer Res 53: 1877-1882, 1993.
5. Dinnen RD, White SR, Elsayed S, Yeh Y and Ebisuzaki K: An endogenous signal triggering erythroid differentiation: Identification as thyroid hormone. Cell Growth Differ 5: 855-861, 1994.
6. De Montmorency A: Ancient South American cancer cure blacked out in America. In: The Spotlight, Washington DC, 10: Jan 5, 1981.
7. A Cancer Journal for Clinicians 43: 309-319, 1993.
8. Hooker SC: The constitution of "lapachic acid" (lapachol) and its derivatives. J Chem Soc 61: 611-650, 1892.
9. Fieser LF, Berliner E, Bondhuse FJ, Chang FC, Dauben WG, Ettinger MO Fawaz G, Fields M, Fieser M, Heidelberger C, Heyman IT, Seligman AM, Vaughn WR, Wilson AG, Wilson W, Wu M-I, Leffler MT, Hamlin KE, Hathaway RJ, Matson EJ, Moore EE, Moore MB, Rapala RT and Zaugg HE: Naphthoquinone antimalarials. I. General survey. J Am Chem Soc 70: 3151-3155, 1948.
10. Rao KV, McBride TJ and Oleson JJ: Recognition and evaluation of lapachol as an antitumor agent. Cancer Res 28:1952-1954, 1968,
11. Block JB, Selpick AA, Miller W, Wiernik PH: Early Clinical studies with lapachol. Cancer Chemother Rep Part 24: 27-9, 1974.
12. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell Y-W, Hunt RW, Trail G, Clogston C, Toso RJ, Yanagihara D, Bennett L, Sylber M, Merewether LM, Tseng A, Escobar E, Liu ET and Yamane HK: Axl receptor tyrosine kinases stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. feature 373: 623-626, 1995.
13. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, Masiakowski P, Ryan TE, Tobkes NJ, Chen DH, DiStefano PS, Long GL, Basilico C, Goldfarb MP, Lemke G, Glass DJ and Yancopoulos GD: The anticoagulation factor protein S and its relative, Gas6, are ligands for the tyro 3/axl family of receptor tyrosine kinases. Cell 80: 661-670, 1995.
14. Gopalakrishnan TV, French-Anderson W: Mouse erythroleukemia cells. Methods Enzymol 58: 506-511, 1979.
15. Patterson MK Jr: Measurement of growth and viability of cells in culture. Methods Enzymol 58: 141-152, 1979.
16. Rittich B, Simek M and Coupek J: Separation of naphthoquinones and lipophilic vitamins by gel and thin-layer chromatography. J Chromatogr 133: 345-348, 1977.
17. Donnahey PL, Burt VT, Rees HH, Pennock JF: High-performance liquid chromatography of menaquinone-4, 2,3-epoxymenaquinone-4, demethylmenaquinone-4 and related compounds. J Chromatogr 170: 272-277, 1979.
18. Murate T, Hotta T, Goto S, Ichikawa A, Inoue C, Kaneda T: Activated charcoal diminishes the lot difference of fetal bovine sera in erythroid colony formation of human bone marrow cells. Proc Soc. Exp Biol (NY) 189:66-71, 1988.
19. Murate T, Kaneda T: Treatment of fetal bovine serum with activated charcoal enhances spontaneous differentiation of murine erythroleukemia cells. Leuk Res 13:227-231, 1989.
20. Garg LC and Brown JC: Friend erythroleukemia cell differentiation: Induction by retinoids. Differentia 25: 79-83, 1983.
21. Elliott S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D, Wright S and Timms P: Proof of differentiation mode of action of all-trans retinoic acid in acute promyelocytic leukemia using x-linked clonal analysis. Blood 79:1916-1919, 1992.
22. Smith MA, Parkinson DR, Cheson BD and Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992.
23. Farrell N, Kelland LR, Roberts JD and Van Beusichem M: Activation of the trans geometry in platinum antitumor complexes: A survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52: 5065-5072, 1992.
24. Zamble DB and Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439, 1995.
25. Ebert PS, Wars I, Buell DN: Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors. Cancer Res 36: 1809-1813, 1976.
26. Weisenthal LM: In vitro assays in preclinical antineoplastic drug screening. Semin Oncol 8: 362-376, 1981.
27. Marks PA, Rifkind RA: Erythroleukemic differentiation. Annu Rev Biochem 47: 419-448, 1978.
28. Francis GE: Theoretical and practical considerations in screening strategies for differentiation agents. Differentia 57: 63-75, 1994.
29. Dowd P, Ham S-W, Naganathan S and Hershline R: The mechanism of action of vitamin K. Annu Rev Nutr 15: 419-440, 1995.
30. Preusch PC and Suttie JW: Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase. Archivs Biochem Biophys 234: 405-412, 1984.
31. Manfioletti G, Brancolini C, Avanzi G and Schneider C: The protein encoded by a growth arrest-specific gene (gas6) is a new menber of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13: 4976-4985, 1993.
32. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C Espinosa R, Le Beau MM, Earp HS and Liu ET: axl, a transforming gene isolated from primary human myeloid luekemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031, 1991.
33. Rescigno J, Mansukhani A and Basilico CA: Putative receptor tyrosine kinase with unique structual topology. Oncogene 6: 1909-1913, 1991.
34. Bellosta P, Costa M, Lin DA, and Basilico C: The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15: 614-625, 1995.
35. Janssen JWG, Schulz AS, Steenvoorden ACM, Schmidberger M, Strehl S, Ambros PF and Bartram CR: A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6: 2113-2120, 1991.
36. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, and Cance WG: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797, 1995.
37. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL, and Green MRA: Randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the cancer and leukemia group B. J Clin Oncol 7: 993-1002, 1989.
38. Chlebowski RT, Gota CH, Chan KK, Weiner JM, Block JB, and Bateman JR: Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 42: 4827-4830, 1982.
39. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards R, Headley E, Kim S-H, O'Donnell JR, O'Dell R, Tornyos K and Kwaan HC: Effect of warfarin on survival in small Cell carcinoma of the lung. Veterans Administration Study No. 75. J Am Med Asso 245: 831-835, 1981.